Merck KGaA CFO Helene von Roeder discusses the group's third-quarter earnings and its progress with drug trials.

Germany’s Merck KGaA expects annual sales to be at the lower half of its outlook range after third-quarter sales missed ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

Merck KGaA reported a 16.6% decline in contract manufacturing due to an unrepeated Covid-19 contract, though overall life ...

Investing.com -- Shares of Merck KGaA (ETR: MRCG) fell over 4% on Thursday following a mixed reception to its third-quarter ...

Merck KGaA’s $70 million bet on a treatment for a rare, locally aggressive cancer has delivered a phase 3 win. The ...

(Bloomberg) -- Merck KGaA posted earnings that topped estimates as its life science unit recovers from its post-pandemic ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Merck KGaA said its cell-tumor treatment Pimicotinib met its primary endpoint in a late-stage trial. The German pharma company said Tuesday that its experimental drug showed significant improvement in ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

BusinessWire India Accra [Ghana] Mumbai Maharashtra [India] November 14 Merck Foundation the philanthropic arm of Merck KGaA ...